UBS Group’s DNA X Inc SONM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9K | Sell |
2,304
-33,915
| -94% | -$150K | ﹤0.01% | 8476 |
|
|
2026
Q1 | $146K | Buy |
36,219
+27,537
| +317% | +$130K | ﹤0.01% | 6803 |
|
|
2025
Q4 | $27.3K | Buy |
8,682
+8,474
| +4,074% | +$76K | ﹤0.01% | 7584 |
|
|
2025
Q3 | $2.26K | Sell |
208
-2,807
| -93% | -$32.5K | ﹤0.01% | 9195 |
|
|
2025
Q2 | $66.2K | Buy |
3,015
+2,029
| +206% | +$50K | ﹤0.01% | 7550 |
|
|
2025
Q1 | $38K | Buy |
+986
| New | +$47.1K | ﹤0.01% | 7784 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 9850 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 9403 |
|
|
2024
Q2 | – | Sell |
-28
| Closed | -$3.04K | – | 10042 |
|
|
2024
Q1 | $3.04K | Buy |
+28
| New | +$3.44K | ﹤0.01% | 7782 |
|
|
2023
Q4 | – | Sell |
-1
| Closed | -$66 | – | 9842 |
|
|
2023
Q3 | $66 | Buy |
+1
| New | +$140 | ﹤0.01% | 8964 |
|
|
2023
Q1 | – | Sell |
-257
| Closed | -$19.9K | – | 10313 |
|
|
2022
Q4 | $19.9K | Buy |
+257
| New | +$21.1K | ﹤0.01% | 7650 |
|
|
2021
Q4 | – | Sell |
-9
| Closed | -$4K | – | 10664 |
|
|
2021
Q3 | $4K | Buy |
+9
| New | +$6.83K | ﹤0.01% | 8679 |
|
|
2021
Q2 | – | Sell |
-6
| Closed | -$9K | – | 9785 |
|
|
2021
Q1 | $9K | Buy |
+6
| New | +$10.6K | ﹤0.01% | 8022 |
|
|
2020
Q4 | – | Sell |
-10
| Closed | -$15K | – | 8721 |
|
|
2020
Q3 | $15K | Hold |
10
| – | – | ﹤0.01% | 6533 |
|
|
2020
Q2 | $15K | Buy |
10
+7
| +233% | +$11.2K | ﹤0.01% | 6748 |
|
|
2020
Q1 | $4K | Sell |
3
-7
| -70% | -$33.5K | ﹤0.01% | 7414 |
|
|
2019
Q4 | $68K | Buy |
10
+8
| +400% | +$39.5K | ﹤0.01% | 6197 |
|
|
2019
Q3 | $8K | Buy |
2
+1
| +100% | +$15.3K | ﹤0.01% | 7291 |
|
|
2019
Q2 | $28K | Buy |
+1
| New | +$25.4K | ﹤0.01% | 6388 |
|
Other funds holding SONM
CWM
VCM
VFT
TRCT
SS
UBS Group's SONM Position: Q2 2026 in Review
UBS Group reduced its DNA X Inc (SONM) stake by 94% in Q2 2026, selling an estimated $150K and leaving 2,304 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8476.
UBS Group first reported a position in SONM in Q2 2019 and has held it in 17 quarters since. The position peaked at $146K in Q1 2026. 8 funds tracked by Wall St. Rank hold SONM as of Q2 2026.
- UBS Group held 2,304 shares of DNA X Inc worth $11.9K as of Q2 2026.
- UBS Group sold 33,915 DNA X Inc shares in Q2 2026, an estimated $150K.
- DNA X Inc made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8476 holding.
- UBS Group first reported a position in DNA X Inc in Q2 2019 and has held it in 17 quarters since.
- UBS Group's DNA X Inc position peaked at $146K in Q1 2026.
- 8 funds tracked by Wall St. Rank held DNA X Inc as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.